Full-Time
Head of Commercial
Amlitelimab
Confirmed live in the last 24 hours
Sanofi
10,001+ employees
Develops pharmaceuticals and vaccines globally
Compensation Overview
$258.8k - $431.3k/yr
Expert
No H1B Sponsorship
Cambridge, MA, USA
Company-paid relocation benefits may be offered for this position. Candidates must be legally eligible to work in the U.S.
- A minimum of a Bachelor's degree is required; advanced degree (MD, PhD or MBA) is preferred
- A minimum of 12 years of overall progressive experience in Pharmaceutical/Biotech Marketing, Sales leadership, and/or General Management roles in the U.S. is required
- Proven experience in leading and developing a formal team of professionals is essential for this role
- Experience leading Biopharma Commercial Teams within Marketing and Sales responsibilities is required
- Proven track record of successful U.S. product launches and lifecycle management in specialty therapeutics is required
- Immunology experience is required; atopic dermatitis knowledge preferred
- This position may require up to 25% overall travel.
- Develop and execute a comprehensive US commercial launch strategy that ensures precision, excellence, and market impact
- Build and lead a best-in-class commercial organization across marketing, sales, thought leader engagement, and market access
- Drive cross-functional collaboration with Global Business Team, Medical, Manufacturing and Supply, Commercial Operations, Market Access, and Corporate Affairs Commercial Strategy & Execution
- Lead marketing team to create compelling brand positioning and marketing strategies that deliver on business objectives and patient needs
- Lead customer-facing teams to build strong relationships with healthcare providers, KOLs, and payers
- Navigate the complex US access environment with innovative approaches to ensure optimal patient access
- Implement digital-forward strategies that enhance customer engagement and drive brand performance
- Deliver on sales, profit, and market share targets within agreed budgets
- Manage P&L accountability, long-range planning, and financial forecasting
- Ensure operational efficiency across all aspects of the business
- Allocate resources strategically to maximize impact and ROI
- Build and inspire a diverse, high-performing commercial team that drives innovation, excellence, and plays to win
- Develop key talent and create a culture of inclusion, collaboration, and continuous improvement
- Foster strong partnerships across functions to ensure aligned objectives and seamless implementation.
- Advanced degree (MD, PhD or MBA) is preferred
- Prior General Management experience is preferred
- Current or prior experience in establishing/building a formal team is preferred
- Atopic dermatitis knowledge preferred
Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new therapies for conditions in immunology, oncology, and rare diseases, as well as producing vaccines. Sanofi's products are designed to meet the needs of patients, healthcare professionals, and governments, offering a wide range of prescription medicines and over-the-counter products. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and extensive R&D efforts, which are supported by strategic partnerships and a diverse product pipeline. The company's goal is to improve health outcomes and enhance the quality of life for people globally by delivering effective and safe healthcare solutions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Simplify's Take
What believers are saying
- Sanofi reported a 20% profit growth in Q1 2025, driven by Dupixent.
- The acquisition of Dren Bio enhances Sanofi's biopharmaceutical capabilities.
- Sanofi's investment in Innate Pharma supports its strategic partnership and pipeline expansion.
What critics are saying
- Increased competition in immunology could impact Dupixent's market share.
- Potential delays in EU approval for tolebrutinib may affect revenue projections.
- Integration challenges from Dren Bio acquisition could pose financial risks.
What makes Sanofi unique
- Sanofi's Dupixent is the first targeted therapy for chronic spontaneous urticaria.
- Tolebrutinib is the first brain-penetrant BTK inhibitor for multiple sclerosis.
- Sanofi's global reach allows it to navigate diverse regulatory environments effectively.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.
Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks
Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosisTolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MSTolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS), where there are currently no treatment options approved. These findings further support the differentiated mechanism of oral, brain-penetrant tolebrutinib, targeting disability progression independent of relapse activity. These results were first presented at the ECTRIMS conference on September 20, 2024 in Copenhagen, Denmark and further analyses were also presented today during the Clinical Trials Plenary Session at the 2025 Annual Meeting for the American Academy of Neurology (AAN) in San Diego, California.Robert Fox, MDVice Chair of Research at Cleveland Clinic’s Neurological Institute, Cleveland, Ohio, US, and chair of the HERCULES global steering committee“Tolebrutinib represents a new class of therapy for the treatment of multiple sclerosis. In this large phase 3 study, tolebrutinib was found to slow the progression of disability in a subset of multiple sclerosis for which we have no approved therapies – non-relapsing secondary progressive disease. The results of this study signal a new chapter in multiple sclerosis because we finally found a potential way to treat non-relapsing secondary progressive forms.”Dr Fox is a paid advisor to Sanofi for the HERCULES study.Erik Wallström, MD, PhDGlobal Head of Neurology Development“By targeting disability progression mechanisms behind the blood-brain barrier, tolebrutinib has the potential to be a practice-changing therapeutic option for people living with multiple sclerosis
If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activityTolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in MSTolebrutinib was granted breakthrough therapy designation by the FDA based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MSParis, March 25, 2025. The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients. The target action date for the FDA decision is September 28, 2025. A regulatory submission is also under review in the EU.The regulatory submissions in the US and the EU are supported by the results from the phase 3 studies HERCULES in nrSPMS and GEMINI 1 and 2 in relapsing MS (RMS). The findings from these studies, as well as additional clinical and preclinical studies, support the differentiated mechanism of tolebrutinib to target disability progression independent of relapse activity, and the scientific hypothesis that smoldering neuroinflammation represents a key inflammatory process in MS and is a critical driver of disability accumulation.Erik Wallström, MD, PhDGlobal Head of Neurology Development“The totality of data across our clinical program validates our scientific understanding of smoldering neuroinflammation as a distinct inflammatory process in MS. People living with non-relapsing secondary progressive multiple sclerosis or who experience disability independent of relapse activity suffer from disability that worsens over time due to persistent inflammation in the brain, known as smoldering neuroinflammation, which is the primary driver of disability